ARM Heads Into Earnings With Analysts Divided on Royalty Ramp

ARM reports fiscal Q1 2027 results today with the stock up 11% on the week to $261.53 — a sharp rebound after a 7.4% pullback over the prior month. The borrow market is relaxed rather than charged: availability runs at roughly 371%, well into normal territory, and cost to borrow is a negligible 0.43%. Options positioning is similarly calm, with the put/call ratio at 1.19 — essentially flat against its 20-day average and carrying no directional signal heading into the print.

The real tension lives in the analyst community. Following the last earnings release in late July, the Street broadly trimmed targets while holding positive ratings — a pattern that captures the core debate precisely. UBS and TD Cowen both cut by $40 or more yet kept Buy-equivalent ratings. RBC cut its target from $475 to $340 while staying at Outperform. Morgan Stanley moved the opposite way, nudging its Equal-Weight target up to $212 — well below the current price, flagging genuine skepticism about the valuation. The consensus mean target of $288 sits only modestly above today's close, suggesting the Street sees limited near-term upside even in the bull case. Bulls anchor on ARM's guided 20% royalty revenue CAGR through 2031, accelerating Armv9 adoption, and a CPU product line that management projects could generate $15 billion in revenue by fiscal 2031 as the company pushes deeper into cloud AI infrastructure. Bears counter that design services revenue is shrinking as a share of the mix, SoftBank's ~86% ownership stake and ~15% revenue contribution introduce concentration risk, and the stock's P/E above 90x leaves almost no room for execution misses.

The ownership structure is itself a defining feature of the setup. SoftBank holds 86.4% of shares — an unusually tight free float that amplifies price moves in either direction. Among institutional holders, several names added meaningfully in recent quarters: Invesco added over 7.6 million shares through June, Arrowstreet added 3.1 million, and Capital Research built a position of 9 million shares through August. Insider activity tells a quieter story; CFO Jason Child sold $2.7 million of stock under a pre-arranged 10b5-1 plan in late August — a scheduled sale, not a discretionary signal — and the broader 90-day net insider position is modestly negative at roughly $9.7 million in sales. Past earnings reactions offer some context: the July 2026 print produced an immediate 1.3% decline before the stock rallied 12% over the subsequent five trading days, suggesting the market has historically needed time to digest ARM results before committing to a direction.

The print will test whether the royalty ramp that management has repeatedly outlined is translating into numbers fast enough to justify a multiple that still prices in near-perfection.